JP2013517273A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517273A5
JP2013517273A5 JP2012549000A JP2012549000A JP2013517273A5 JP 2013517273 A5 JP2013517273 A5 JP 2013517273A5 JP 2012549000 A JP2012549000 A JP 2012549000A JP 2012549000 A JP2012549000 A JP 2012549000A JP 2013517273 A5 JP2013517273 A5 JP 2013517273A5
Authority
JP
Japan
Prior art keywords
amino
methyl
pyrimidinyl
benzenesulfonamide
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012549000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020798 external-priority patent/WO2011088027A1/en
Publication of JP2013517273A publication Critical patent/JP2013517273A/ja
Publication of JP2013517273A5 publication Critical patent/JP2013517273A5/ja
Pending legal-status Critical Current

Links

JP2012549000A 2010-01-13 2011-01-11 化合物および方法 Pending JP2013517273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29463710P 2010-01-13 2010-01-13
US61/294,637 2010-01-13
PCT/US2011/020798 WO2011088027A1 (en) 2010-01-13 2011-01-11 Compounds and methods

Publications (2)

Publication Number Publication Date
JP2013517273A JP2013517273A (ja) 2013-05-16
JP2013517273A5 true JP2013517273A5 (enExample) 2014-02-20

Family

ID=44304601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549000A Pending JP2013517273A (ja) 2010-01-13 2011-01-11 化合物および方法

Country Status (13)

Country Link
US (1) US20120329784A1 (enExample)
EP (1) EP2523559A4 (enExample)
JP (1) JP2013517273A (enExample)
KR (1) KR20120114355A (enExample)
CN (1) CN102791131A (enExample)
AU (1) AU2011205485B2 (enExample)
BR (1) BR112012017277A2 (enExample)
CA (1) CA2786999A1 (enExample)
EA (1) EA201290642A1 (enExample)
IL (1) IL220812A0 (enExample)
MX (1) MX2012008141A (enExample)
SG (1) SG182351A1 (enExample)
WO (1) WO2011088027A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164323A1 (en) * 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
ES2834430T3 (es) * 2013-03-15 2021-06-17 Univ Southern California Procedimientos, compuestos y composiciones para el tratamiento de enfermedades relacionadas con la angiotensina
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN104844526B (zh) * 2015-04-16 2018-08-31 温州医科大学 一种4,6-嘧啶二胺类化合物及其制备方法和应用
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
JP6165373B1 (ja) * 2017-02-24 2017-07-19 タマ化学工業株式会社 ピリジン−3−スルホニルクロリドの製造方法
EP3630291B9 (en) * 2017-05-26 2024-05-29 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
IL296734B2 (en) 2018-04-13 2025-06-01 The Institute Of Cancer Res Royal Cancer Hospital Bcl6 inhibitors
CN108864052A (zh) * 2018-06-07 2018-11-23 福建医科大学 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
EP4206196A1 (en) * 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
WO2023196714A2 (en) * 2022-02-23 2023-10-12 President And Fellows Of Harvard College Inhibitors of ddr1 and ddr2 for the treatment of arthritis
PL4496795T3 (pl) 2022-03-23 2026-07-20 Ideaya Biosciences, Inc. Związki indazolowe podstawione piperazyną jako inhibitory parg
US11891362B1 (en) * 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents
JP2026520429A (ja) * 2023-05-23 2026-06-23 クオントエックス バイオサイエンシーズ ユーエス, インコーポレイテッド 二環式ヘテロアリール化合物
WO2024250010A2 (en) * 2023-06-02 2024-12-05 Atomwise Inc. Inhibitors of tyk2
WO2024249831A2 (en) * 2023-06-02 2024-12-05 Unogen Biotech Ltd. Triple kinase inhibitors
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU2002316421B2 (en) * 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
BRPI0506839A (pt) * 2004-01-16 2007-06-12 Novartis Ag composições e métodos para induzir a cardiomiogênese
US20080242681A1 (en) * 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
UA109411C2 (uk) * 2005-11-01 2015-08-25 N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2007257650A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
CN101589036A (zh) * 2006-12-19 2009-11-25 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶
US7947698B2 (en) * 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
JP5600063B2 (ja) * 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ, インコーポレイテッド ヘテロアリール化合物およびその使用

Similar Documents

Publication Publication Date Title
JP5555169B2 (ja) 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
RU2312860C2 (ru) Циклические ингибиторы протеинтирозинкиназ
US20120329784A1 (en) Compounds and methods
JP2013517283A5 (enExample)
ES2610158T3 (es) Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
JP2014511869A5 (enExample)
CA2582029A1 (en) Aryl nitrogen-containing bicyclic compounds and methods of use
JP2007523905A5 (enExample)
RU2007100136A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NZ597528A (en) Inhibitors of flaviviridae viruses
RU2009116670A (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
PT1725544E (pt) 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
ZA200606880B (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
CA2564355A1 (en) Protein kinase modulators and method of use
ZA200505184B (en) Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
JP2007519754A5 (enExample)
JP2013519733A5 (enExample)
JP2004517925A5 (enExample)
JP2010513444A5 (enExample)
JP2003534336A5 (enExample)
CN102076671A (zh) 三唑衍生物或其盐
HRP20100283T1 (hr) Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor
JP2014513122A5 (enExample)
RU2367659C2 (ru) Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)